⌘K
Loading ticker…
As of 2026-08-24, Clorox Company (CLX) has a 3-month relative strength percentile of 71 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 49. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 2.8%, relative volume 0.67×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
CLX is held by 57 ETFs as of May 2026. Top owner: NOBL at 1.32% weight, $147M notional. Top 3 carry $245M.
Held by 216 ETFs · $3.2B across latest filings · largest weight 4.40% (MVAL).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| NOBLProShares S&P 500 Dividend Aristocrats ETF | 1.32% | $147M | −0.27 pp |
| SPHD | 1.69% | $55M | −0.54 pp |
| VDCVanguard Consumer Staples ETF | 0.47% | $43M | −0.13 pp |
| SCHMSchwab U.S. Mid-Cap ETF | 0.20% | $29M | −0.11 pp |
| ESGU | 0.10% | $17M | −0.11 pp |
| SCHXSchwab U.S. Large-Cap ETF | 0.02% | $12M | — |
| RDIV | 0.81% | $9M | −0.39 pp |
| VONVVanguard Russell 1000 Value ETF | 0.03% | $7M | −0.02 pp |
| SCHBSchwab U.S. Broad Market ETF | 0.02% | $7M | — |
| SCHVSchwab U.S. Large-Cap Value ETF | 0.04% | $6M | −0.02 pp |
Showing 10 of 57 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CLX Jan avg: 3.63% median: 2.49% win: 75% σ: 5.95% n: 4 2022-04-12 → 2026-07-31 | CLX Feb avg: 6.07% median: 6.49% win: 75% σ: 5.86% n: 4 2022-04-12 → 2026-07-31 | CLX Mar avg: -5.67% median: -2.99% win: 25% σ: 9.15% n: 4 2022-04-12 → 2026-07-31 | CLX Apr avg: -2.39% median: -3.36% win: 20% σ: 4.26% n: 5 2022-04-12 → 2026-07-31 | CLX May avg: -5.64% median: -6.66% win: 20% σ: 4.54% n: 5 2022-04-12 → 2026-07-31 | CLX Jun avg: -0.33% median: 0.54% win: 60% σ: 5.90% n: 5 2022-04-12 → 2026-07-31 | CLX Jul avg: -0.56% median: 0.09% win: 60% σ: 3.65% n: 5 2022-04-12 → 2026-07-31 | CLX Aug avg: 4.79% median: 2.52% win: 75% σ: 10.90% n: 4 2022-04-12 → 2026-07-31 (current) | CLX Sep avg: -5.01% median: -4.07% win: 50% σ: 10.20% n: 4 2022-04-12 → 2026-07-31 | CLX Oct avg: -1.98% median: -5.73% win: 25% σ: 10.98% n: 4 2022-04-12 → 2026-07-31 | CLX Nov avg: 6.25% median: 3.61% win: 75% σ: 11.07% n: 4 2022-04-12 → 2026-07-31 | CLX Dec avg: -3.89% median: -4.22% win: 0% σ: 2.74% n: 4 2022-04-12 → 2026-07-31 |